Abstract: This invention relates to an apparatus and method for the simultaneous and rapid determination of CoQ10 and CoQ10H2 concentrations in human samples using HPLC-EC. The electrochemical reactions are monitored at electrodes that measure the current produced by the reduction of the hydroquinone group of CoQ10 or by the oxidation of the hydroquinol group of CoQ10H2.
Type:
Grant
Filed:
March 4, 2002
Date of Patent:
January 10, 2006
Assignee:
Cincinnati Children's Hospital Research Foundation
Inventors:
Peter H. Tang, Ton de Grauw, Michael V. Miles
Abstract: The present invention provides novel compositions comprising Epstein-Barr virus-specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification. The invention also provides a rapid, sensitive and specific method for the detection and quantitation of the virus which may be present in a clinical specimen, using the virus-specific primers and enzymatic nucleic acid amplification; hybridization of amplified target sequences, if present, with one or more Epstein-Barr virus-specific oligonucleotide probes which are labeled with a detectable moiety; and detection of the detectable moiety of labeled oligonucleotide probe hybridized to amplified target sequences of Epstein-Barr virus DNA.
Type:
Grant
Filed:
February 13, 2002
Date of Patent:
September 14, 2004
Assignee:
Cincinnati Children's Hospital Research Foundation
Abstract: The present invention provides novel compositions comprising Epstein-Barr virus-specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification. The invention also provides a rapid, sensitive and specific method for the detection and quantitation of the virus which may be present in a clinical specimen, using the virus-specific primers and enzymatic nucleic acid amplification; hybridization of amplified target sequences, if present, with one or more Epstein-Barr virus-specific oligonucleotide probes which are labeled with a detectable moiety; and detection of the detectable moiety of labeled oligonucleotide probe hybridized to amplified target sequences of Epstein-Barr virus DNA.
Type:
Application
Filed:
February 13, 2002
Publication date:
September 18, 2003
Applicant:
Cincinnati Children's Hospital Research Foundation
Abstract: The invention relates to a method of treating non-psychotic disorders by administration of atypical antipsychotic medications, in particular, risperidone. More specifically, the invention relates to a method of treating the eating disorder Bulimia Nervosa and Bulimia-related eating disorders, by administration of antipsychotic medications from the group of compounds designated as atypical antipsychotic mediations. Typical dosage amounts may range from 0.1 milligrams to 4 milligrams per day and may be administered in any dosage forms known in the art, including, but not limited to oral, intramuscular, rectal, transdermal, sustained release forms, controlled release forms, delayed release forms, and response release forms.
Type:
Grant
Filed:
March 17, 2000
Date of Patent:
May 28, 2002
Assignee:
The Cincinnati Children's Hospital Research Foundation